A new study published in Nature Communications highlights PRL3-zumab, a drug effectively combating major causes of vision loss.
Originally developed in Singapore as an anti-cancer agent, the drug PRL3-zumab now shows immense potential as a revolutionary treatment for two primary causes of blindness: wet age-related macular degeneration (AMD) and diabetic retinopathy. Preclinical study results, published in Nature Communications, demonstrated that PRL3-zumab significantly reduced fluid leakage from damaged eye vessels, a key factor in vision deterioration for these conditions.
Current treatment methods often necessitate monthly injections directly into the eye, with up to 45% of patients showing little to no response. In contrast, PRL3-zumab was administered intravenously and exhibited an 86% greater effect compared to standard intraocular injections. Furthermore, this method of administration provided more stable therapeutic drug levels without the risks associated with direct eye injections.
PRL3-zumab has already successfully completed Phase II clinical trials as an anti-cancer drug, confirming its acceptable safety profile. Encouraged by these promising outcomes, researchers are now preparing to initiate clinical trials for ophthalmic diseases by late 2025. This development offers a significant opportunity for millions of patients worldwide to preserve or restore their sight.
It is also worth noting that scientists have previously made progress in retinal regeneration. Specifically, experiments on mice demonstrated that blocking the PROX1 protein stimulated Müller cells to transform into new neurons, thereby contributing to vision restoration.
